B-SMART - Broadly neutralizing antibodies for SaRNA Mediated Antiviral Response Therapy PHS2025-1
Summary
AI-generated · Aug 27, 2025Three distinct research awards have been issued for: (1) a therapeutic vaccine platform to boost immune responses in tuberculosis; (2) evaluating HBVZ10-based therapies for cccDNA clearance, focusing on virological foundations and synergistic combinations; and (3) B-SMART, developing broadly neutralizing antibodies for SaRNA-mediated antiviral response therapy. No bid-specific requirements, brand-name constraints, site visits, or certifications are described in the notices provided.
Awardees and amounts are: L2 Diagnostics LLC ($599,471.00), HBVTECH, L.L.C ($2,656,170.00), and LYNNTECH INC. ($599,989.00); all awards issued on the same date. The notices list the project titles and funding amounts but do not provide additional solicitation, scope details, deliverables, or post-award obligations beyond what is shown.
Notice history
3-
-
Award Notice Posted Jul 31, 2025
-
Award Notice LATEST Posted Jul 31, 2025
Details
Award Information
Awardees
| Company Name | UEI | CAGE Code | Location |
|---|---|---|---|
| L2 DIAGNOSTICS LLC | GKA7VH5LFR25 | 43BA5 | New Haven, CT |
| HBVTECH, L.L.C | WEXNYHY4EZB5 | 6WC76 | Germantown, MD |
| LYNNTECH INC. | PMVAL8J63516 | 0LHF9 | College Station, TX |
Contacts
Phone
Phone
Agency
Place of Performance
USA